viewImugene Ltd

Imugene director increases stake, capital raising underway

Paul Hopper is an Australian biotech entrepreneur who has been associated with a number of biotechnology companies.

Imugene Ltd - Imugene director increases stake, capital raising underway
Shares in the company last traded at 4.4 cents before being halted

Imugene Ltd (ASX:IMU) non-executive director Paul Hopper has increased his shareholding in the company substantially.

He recently acquired 100.9 million shares increasing his overall holding to 177.1 million shares, more than doubling his stake.

Shares in the company entered a trading halt yesterday pending the release of details regarding a capital raising.

Industry sources suggest Imugene is raising up to $24.6 million through a placement priced at 3.6 cents with attaching options.

The raising is being led by brokers Bell Potter and Aurenda Partners.

Imugene is a clinical-stage biotech company developing a range of immunotherapies that seek to activate the immune system of cancer patients to treat tumors.



Quick facts: Imugene Ltd

Price: 0.034 AUD

Market: ASX
Market Cap: $150.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read